$GBHL Global Entmt Hld Inc (GBHL) 0.0500 unch (unch)
$GBHL
Global Entmt Hld Inc (GBHL)
0.0500 unch (unch)
Past 5 Days
Date Open High Low Last Change % Change Volume
02/12/14 0.0500 0.0500 0.0500 0.0500 unch unch 20,800
02/11/14 0.0500 0.0500 0.0500 0.0500 unch unch 17,100
02/10/14 0.0500 0.0500 0.0500 0.0500 unch unch 17,000
02/07/14 0.0250 0.0500 0.0250 0.0500 unch unch 9,500
02/06/14 0.0500 0.0500 0.0500 0.0500 unch unch 87,300
Historical Highs and Lows
-- Period -- -- High -- -- Low -- -- Percent Change --
5-Day 0.0500 on 02/12/14 0.0250 on 02/07/14 unch since 02/05/14
1-Month 0.0700 on 02/04/14 0.0250 on 02/07/14 +100.00% since 01/09/14
3-Month 0.0700 on 02/04/14 0.0100 on 12/10/13 +100.80% since 11/12/13
6-Month 0.0870 on 08/20/13 0.0100 on 12/10/13 unch since 08/09/13
12-Month 0.1600 on 03/04/13 0.0070 on 02/19/13 unch since 02/12/13
Year to Date 0.0700 on 02/04/14 0.0200 on 01/02/14 +278.79% since 12/30/13
New Highs and Lows
For The Last Made New High Percent From Made New Low Percent From
5-Day 5 times unch 2 times +100.00%
1-Month 9 times -28.57% 5 times +100.00%
3-Month 15 times -28.57% 5 times +400.00%
6-Month 2 times -42.53% 14 times +400.00%
12-Month 8 times -68.75% 2 times +614.29%
Year to Date 11 times -28.57% 1 time +150.00%
Scroll down for more posts ▼
Top 10 Most Recent News Articles
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
Top 5 Most Recently Viewed Articles
Endava got tangled in a class action lawsuit over securities fraud back in 2024. Investors were already feeling the squeeze as whispers about declining demand for its services echoed through the trading floor. You know how it goes—when rumors hit, shares take a dive faster than you can blink. Class Action Reality: Who Gets to Play? The lawsuit targeted shareholders who...
Continue Reading
Introduction to Deephaven Residential Mortgage Trust 2024-1 In an important development within the non-prime mortgage market, KBRA has recently assigned preliminary ratings to eight classes of mortgage-backed notes from Deephaven Residential Mortgage Trust 2024-1 (DRMT 2024-1). This $514.6 million transaction comprises a unique pool of 1,330 residential mortgages,...
Continue Reading
Quarterly Cash Dividend Announcement from Meta Platforms The board of directors of Meta Platforms, Inc. (NASDAQ: META) has recently declared a quarterly cash dividend of $0.525 per share, benefitting shareholders holding both Class A and Class B common stock. This dividend reflects the company's ongoing commitment to returning value to its shareholders. Dividend Payment...
Continue Reading
Campine NV Forecasts Impressive Growth in 2024 Campine NV, a well-known name in the metals recycling and specialty chemicals sector, is gearing up for a promising financial year ahead. The company has recently indicated that it anticipates higher profits in 2024, thanks to favorable market conditions. Projected Revenue Growth for 2024 According to Campine's expectations,...
Continue Reading
Thumzup Media's Strategic Move into Dogecoin Thumzup Media Corporation (Nasdaq: TZUP) has made headlines with its latest purchase of Dogecoin, securing around 7.5 million tokens valued at approximately $2 million. This significant acquisition marks the company's first open-market investment in Dogecoin, reflecting a strong belief in the digital currency's potential for...
Continue Reading